Milton Mutchnick

Prof. Dr. Milton Mutchnick


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MIMohamad Itani
Mohamad Itani
BFBassem Farah
Bassem Farah
MWMargaret Wasvary
Margaret Wasvary
AWAnshu Wadehra
Anshu Wadehra
TWTj Wilson
Tj Wilson
MMMilton Mutchnick
Milton Mutchnick

25 July 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
ASAstha Saini
Astha Saini
BRBrian P Rutledge
Brian P Rutledge
ADAnirudh Damughatla
Anirudh Damughatla
MRMina Saad Rasheed
Mina Saad Rasheed
PNP.aul H Naylor
P.aul H Naylor
MMMilton Mutchnick
Milton Mutchnick
African Americans (AA) have a high incidence of risk factors associated with MASLD (metabolic dysfunction-associated steatotic liver disease); the AA population has a lower incidence of MASLD and MASH (metabolic-associated steatotic hepatitis) than Caucasian and Hispanic Americans (non-AA). We investigated if underlying risk factor variation between AA and non-AA individuals could provide a rationale for the racial diversity seen in MASLD/MASH. Using ICD-10 codes, patients from 2017 to 2020 with MASLD/MASH were identified and confirmed to have either MASLD or MASH. Despite the large (>80%) AA population in our clinics, only 54% of the MASLD/MASH patients were African American. When the non-invasive NAFLD Fibrosis Scores (NFS) evaluated at early diagnosis were compared to the most recent values, the only increase in fibrosis score by NFS over time was in non-AA MASH patients. The increase in fibrosis only in non-AA MASLD patients is consistent with racial disparity in the disease progression in non-AA as compared to AA patients. Even with the large proportion of AA patients in our study, there was no significant racial disparity in the earliest assessment of either risk factors, laboratory values, or fibrosis scores that would account for racial disparity in the development and progression of MASLD.

1 April 2018 in Pancreas
Verified
Journal Article
Closed access
ZKZiad Kanaan
Ziad Kanaan
AZAllison Zhang
Allison Zhang
KLKirthi Lilley
Kirthi Lilley
MMMilton Mutchnick
Milton Mutchnick

20 December 2018 in Cureus
Verified
Journal Article
Open access
PDF file
AAAhmad A Abu-Heija
Ahmad A Abu-Heija
MSMaya Shatta
Maya Shatta
AYAhmed Yeddi
Ahmed Yeddi
ARAnand Kumar Ravi
Anand Kumar Ravi
MMMilton Mutchnick
Milton Mutchnick
Acute retroviral syndrome (ARS) can present as a wide array of clinical manifestations. Establishing a diagnosis early in the disease course can provide an opportunity to minimize immunosuppression and limit further transmission of human immunodeficiency virus (HIV). We present a case of a previously healthy young male who presented with acute hepatitis, as a manifestation of ARS. Initial HIV antigen/antibody testing was negative; however, a high index of suspicion prompted HIV ribonucleic acid (RNA) virologic testing revealing >10 million RNA copies/mL. Anti-retroviral treatment was initiated, along with supportive measures, accomplishing resolution of the transaminitis and the restoration of CD4 counts within normal at one month. Early in the disease course, HIV screening immunoassay could still be negative; hence, confirmatory testing with HIV RNA virologic testing should be pursued when clinical suspicion is high. Prompt diagnosis and treatment can improve outcome and curtail viral transmission.

30 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
CACrisshy Auguste
Crisshy Auguste
RKRana Khamis
Rana Khamis
PNP.aul H Naylor
P.aul H Naylor
MMMilton Mutchnick
Milton Mutchnick
Background/Objectives: The approval of direct acting antiviral (DAA) therapy for hepatitis C (HCV) resulted in a highly effective oral treatment for patients. The primary objective of this study was to compare patients who were not treated to patients who were treated. Identifying potential reasons for the failure to treat can provide a pathway to interventions using evidence-based data. Methods: The electronic medical records in an urban predominately African American (AA) population were searched for all patients with HCV seen at least once in a GI or ID clinic 2019. Data collected included demographics, treatment visits, laboratory, insurance, and ZIP codes for median income. Results: Of the 441 patients who were not yet treated at the first 2019 visit, only 43% were treated by July 2020. Insurance and median income were not factors in failure to treat. Patients with an average of 4 visits were more likely to be treated than those with 2 or less thus confirming that failure to follow up was a significant factor for patient treatment (42% vs 8% p<0.0001). PCR available at first visit to confirm infection was an important factor with respect to treatment (treated 38% vs not treated 25% p<0.02). Conclusions: Significant numbers of our patients (57%) failed to be treated after at least one clinic visit. The two critical factors were PCR confirmation prior to the initial visit and the requirement for multiple visits before initiation of for treatment. Since the degree of fibrosis had no impact on treatment, initiating treatment immediately after confirming infection with HCV should improve patient treatment rates and outcomes.

30 June 2025 in Onco
Verified
Journal Article
Open access
PDF file
GBGabriel Boudagh
Gabriel Boudagh
AAAhmad Alnasart
Ahmad Alnasart
KCKenan Abou Chaer
Kenan Abou Chaer
PNP.aul H Naylor
P.aul H Naylor
MMMilton Mutchnick
Milton Mutchnick
Background: Hepatocellular carcinoma (HCC) remains a significant global health burden, particularly among vulnerable populations. This retrospective study investigates trends in HCC incidence and age at diagnosis within an urban medical center population, focusing on the impact of hepatitis C virus (HCV) treatment and racial disparities. Methods: The study includes 484 patients diagnosed with HCC between 2000 and 2023. Results: A significant decline in HCC incidence was observed with a peak in incidences between 2015 and 2017 (p < 0.02). The increase and subsequent decline were driven by a decline in HCV-related cases, particularly among the African American (AA) population. This trend was not seen for patients with other risk factors for HCC. An increase in age at diagnosis in HCV patients but not other risk patients was observed in AA (62 vs. 69 years p = 0.001) but not non-AA patients (66 vs. 67 p = 0.16). This increase in age for AA HCV patients could be due to an aging population, changing risk factor profiles, and/or limitations in surveillance and early detection of HCC. Conclusions: This study highlights the critical role of HCV treatment in reducing HCC incidence, particularly within the AA population. These findings emphasize the need for sustained efforts in surveillance, early detection, and targeted prevention strategies to address the evolving epidemiology of HCC and improve outcomes across all populations.